1.41
+0.005(+0.36%)
Currency In USD
| Previous Close | 1.4 |
| Open | 1.42 |
| Day High | 1.42 |
| Day Low | 1.35 |
| 52-Week High | 3.2 |
| 52-Week Low | 1 |
| Volume | 35,189 |
| Average Volume | 767,237 |
| Market Cap | 8.15M |
| PE | -0.84 |
| EPS | -1.68 |
| Moving Average 50 Days | 1.6 |
| Moving Average 200 Days | 2.1 |
| Change | 0.01 |
If you invested $1000 in BioCardia, Inc. (BCDA) 10 years ago, it would be worth $3.6 as of November 03, 2025 at a share price of $1.4. Whereas If you bought $1000 worth of BioCardia, Inc. (BCDA) shares 5 years ago, it would be worth $14.89 as of November 03, 2025 at a share price of $1.4.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial
GlobeNewswire Inc.
Oct 30, 2025 12:00 PM GMT
SUNNYVALE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the first patient enrolled at
BioCardia Regains Compliance with Nasdaq Listing Requirements
GlobeNewswire Inc.
Oct 02, 2025 12:00 PM GMT
SUNNYVALE, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has regained compliance with the Nas
BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure
GlobeNewswire Inc.
Sep 22, 2025 12:00 PM GMT
SUNNYVALE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has had a positive preliminary clin